Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China Accepts Chugai's NDA Submission for Novel Osteoporosis Treatment

publication date: Mar 23, 2018

Chugai Pharma reported that the CFDA accepted its New Drug Application for eldecalcitol, an oral active vitamin D3 derivative for osteoporosis. A Japanese pharma, Chugai is majority-owned (62%) by Roche. In a China Phase III trial, patients treated with eldecalcitol showed greater bone mineral density (BMD) compared to alfacalcidol-treated patients after 12 months. Chugai has marketed eldecalcitol in Japan since 2011. More details....

Stock Symbols: (TYO: 4519) (ROG: SIX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.